LakeShore Biopharma Warrants
LSBPW
LSBPW was delisted on the 19th of September, 2025.
25 hedge funds and large institutions have $447K invested in LakeShore Biopharma Warrants in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 5 closing their positions.
68% more capital invested
Capital invested by funds: $266K → $447K (+$181K)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.57% less ownership
Funds ownership: 5.9% → 5.33% (-0.57%)
11% less funds holding
Funds holding: 28 → 25 (-3)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$1.96K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.22K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SVI
Strategic Vision Investment
Hong Kong
|
-$1.48K |
| 2 |
EC
Elequin Capital
New York
|
-$1.43K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$341 |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$45 |
| 5 |
CS
Clear Street
New York
|
-$13 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
UBS Group
Zurich,
Switzerland
| $5 | +$4 | +68 | New |
|
|
SLM
27
Snow Lake Management
Menlo Park,
California
| – | -$19K | -500,000 | Closed |
|
|
SVI
28
Strategic Vision Investment
Hong Kong
| – | -$1.48K | -38,857 | Closed |
|
|
EC
29
Elequin Capital
New York
| – | -$1.43K | -37,500 | Closed |
|
|
30
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$341 | -12,591 | Closed |
|
|
WAM
31
Wolverine Asset Management
Chicago,
Illinois
| – | -$45 | -1,200 | Closed |
|
LSBPW Hedge Fund Activity: Q1 2024 in Review
25 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q1 2024, worth a combined $447K — up 68% from $266K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LSBPW and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Cowen and Company, adding an estimated $1.96K. The largest seller was Strategic Vision Investment, exiting entirely with an estimated $1.48K sold.
- 25 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q1 2024, down from 28 in Q4 2023.
- Funds reported $447K of LakeShore Biopharma Warrants stock for Q1 2024, up 68% quarter-over-quarter.
- 3 funds opened new LakeShore Biopharma Warrants positions in Q1 2024 and 5 closed out, a net change of -2 holders.
- The largest LakeShore Biopharma Warrants buyer in Q1 2024 was Cowen and Company, an estimated $1.96K added.
- The largest LakeShore Biopharma Warrants seller in Q1 2024 was Strategic Vision Investment, an estimated $1.48K sold.
Based on aggregated 13F filings for Q1 2024.